{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:42:42Z","timestamp":1791315762757,"version":"4.3.1"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Steroid-dependent nephrotic syndrome (SDNS) patients experience frequent relapse or adverse effects on long-term treatment with steroids or cyclophosphamide. This study assessed the efficacy and side effect profile of mycophenolate mofetil (MMF) therapy in children with nephrotic syndrome in our population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective study was performed on children with SDNS who were on MMF therapy for a minimum period of 1\u2009year, and were on regular follow-up in the Department of Nephrology at the Institute of Child Health and hospital for children attached to Madras Medical College.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 87 patients, with a male:female ratio of 2:1. The median age at diagnosis of nephrotic syndrome was 3 years [95% confidence interval (CI): 1\u20138 years], which was found to be a statistically significant risk factor for MMF failure. The median duration of follow-up after initiation of MMF therapy was 3 years and 3 months (95% CI: 1\u2009year and 3 months to 6 years and 6 months). At initial evaluation, 31 (36%) patients presented with SDNS while the remaining had frequently relapsing nephrotic syndrome progressing to SDNS. Intravenous cyclophosphamide was used as first-line therapy in 82 patients, of whom 24 patients had persistent proteinuria while the remaining 58 had attained remission for a median duration of 6\u2009months. The median duration of treatment with MMF was 2 years and 6 months (95% CI: 1\u2009year and 3 months to 4 years and 6 months). MMF was used at a mean dose of 28.5\u2009mg\/kg. Seventy-two (83%) patients were MMF-sensitive, and these patients had a reduction in mean prednisolone dose from 1.28 to 0.35 mg\/kg (P\u2009&amp;lt;\u20090.05). Among the MMF-sensitive patients, 31 had stopped MMF after a minimum period of 2 years, following which they had a median remission period of 5 months (95% CI: 1\u20138 months). MMF failure occurred in 15 (17%) patients. Adverse events were documented in 19 (22%) patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Continuous MMF therapy achieved remission in 83% of patients. MMF was well tolerated in the study population and discontinuation of MMF resulted in 100% relapse.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfz061","type":"journal-article","created":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T03:05:10Z","timestamp":1556334310000},"page":"179-183","source":"Crossref","is-referenced-by-count":13,"title":["The safety and efficacy of mycophenolate mofetil in children and adolescents with steroid-dependent nephrotic syndrome: a single-centre study"],"prefix":"10.1093","volume":"13","author":[{"given":"Saravanakumar","family":"Karunamoorthy","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineshkumar","family":"Thanigachalam","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanapriya","family":"Jeyachandran","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakthirajan","family":"Ramanathan","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopalakrishnan","family":"Natarajan","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasubramaniam","family":"Thoppalan","sequence":"first","affiliation":[{"name":"Institute of Nephrology, Madras Medical College, Chennai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"2020041009152543000_sfz061-B1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/adc.83.1.45","article-title":"Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomized controlled trials","volume":"83","author":"Hodson","year":"2000","journal-title":"Arch Dis Child"},{"key":"2020041009152543000_sfz061-B2","first-page":"CD002290","article-title":"Non-corticosteroid treatment for nephrotic syndrome in children","volume":"1","author":"Hodson","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2020041009152543000_sfz061-B3","first-page":"128","volume-title":"Pediatric Nephrology","author":"Srivastava","year":"2001"},{"key":"2020041009152543000_sfz061-B4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s004670000523","article-title":"A metaanalysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children","volume":"16","author":"Latta","year":"2001","journal-title":"Pediatr Nephrol"},{"key":"2020041009152543000_sfz061-B5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1046\/j.1523-1755.2001.0590051919.x","article-title":"Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials","volume":"59","author":"Durkan","year":"2001","journal-title":"Kidney Int"},{"key":"2020041009152543000_sfz061-B6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1993.tb00652.x","article-title":"Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil","volume":"125","author":"Allison","year":"1993","journal-title":"Immunol Rev"},{"key":"2020041009152543000_sfz061-B7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/kisup.2012.16","article-title":"Chapter 3: steroid-sensitive nephrotic syndrome in children","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2020041009152543000_sfz061-B8","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00467-005-1957-y","article-title":"Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome","volume":"20","author":"Novak","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"2020041009152543000_sfz061-B9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.00550206","article-title":"Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020041009152543000_sfz061-B10","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","article-title":"Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome","volume":"22","author":"Afzal","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"2020041009152543000_sfz061-B11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00467-011-2006-7","article-title":"Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial","volume":"27","author":"Baudouin","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2020041009152543000_sfz061-B12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00467-012-2278-6","article-title":"Outcome of severe steroid-dependent nephrotic syndrome treated with mycophenolate mofetil","volume":"28","author":"Banerjee","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"2020041009152543000_sfz061-B13","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/ckj\/sft071","article-title":"A single-centre retrospective study of the safety and efficacy of mycophenolate mofetil in children and adolescents with nephrotic syndrome","volume":"6","author":"Hassan","year":"2013","journal-title":"Clin Kidney J"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/2\/179\/33028129\/sfz061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/2\/179\/33028129\/sfz061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:15:39Z","timestamp":1586524539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/13\/2\/179\/5512031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,6,6]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz061","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,6,6]]}}}